Ahmed Abdelhak

3 weeks ago | neurologylive.com | Ahmed Abdelhak |Isabella Ciccone

Emerging serum and imaging biomarkers are currently aiming to enhance the ability to monitor remyelination in multiple sclerosis (MS). For example, serum neurofilament light chain (NfL) has emerged as a promising biomarker, reflecting neuroaxonal damage and correlating with disease activity and progression. Recent research has shown that elevated serum NfL levels were associated with an increased risk of disability and brain atrophy.

3 weeks ago | neurologylive.com | Ahmed Abdelhak |Isabella Ciccone

WATCH TIME: 5 minutes "I think we demonstrated in a robust way that if you cause demyelination, neurofilament light (NfL) will go up, and if you remyelinate the axons, NfL levels will be lower." At the recently concluded 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 28-31, 2025, in Phoenix, the session titled “Promoting Remyelination in MS” provided attendees with a comprehensive overview of current scientific, clinical, and translational efforts aimed at...

Apr 12, 2024 | nature.com | Michael Khalil |Sylvain Lehmann |Markus Otto |Fredrik Piehl |Stefan Bittner |Maria Pia Sormani | +8 more

AbstractNeurofilament proteins have been validated as specific body fluid biomarkers of neuro-axonal injury. The advent of highly sensitive analytical platforms that enable reliable quantification of neurofilaments in blood samples and simplify longitudinal follow-up has paved the way for the development of neurofilaments as a biomarker in clinical practice.